Astellas Pharma has submitted a proposal to the board of directors of CV Therapeutics, Inc. to acquire all outstanding shares of CV Therapeutics at a total value of $1.0 billion in cash. Astellas previously made an offer in November 2008 and was rejected. CV Therapeutics has subsequently declined to engage Astellas in discussions regarding a transaction. “We are disappointed that the CV Therapeutics board of directors has rejected outright what we believe is a very compelling all-cash proposa...